| Literature DB >> 26053856 |
Raymond K Hui1, Frederick C Leung2.
Abstract
RNA-Seq was used to unveil the transcriptional profile of DF-1 cells at the early stage of caIBDV infection. Total RNAs were extracted from virus-infected cells at 0, 6 and 12 hpi. RNA-Seq datasets of respective samples mapped to 56.5-57.6% of isoforms in the reference genome Galgal4.73. At 6 hpi, 23 isoforms underwent an elevated expression, while 128 isoforms were up-regulated and 5 were down-regulated at 12 hpi in the virus-infected group. Besides, 10 isoforms were exclusively expressed in the virus-infected cells. Though no significant change was detected in cytokine and interferon expression levels at the first 12 hours of infection, modulations of the upstream regulators were observed. In addition to the reported regulatory factors including EIF2AK2, MX, OAS*A, GBP7 and IFIT, IBDV infection also triggered a IFIT5-IRF1/3-RSAD5 pathway in the DF-1 cells which potentially restricted the viral replication cycle in the early infection stage. Over-expression of LIPA and CH25H, together with the suppression of STARD4, LSS and AACS genes implied a modulation of membrane fluidity and lipid raft arrangement in the infected cells. Alternative splicing of the EFR3 homolog A gene was also through to be involved in the lipid membrane regulation, and these cumulative responses projected an inhibition of viral endocytosis. Recognition of viral RNA genomes and intermediates was presumably enhanced by the elevated levels of IFIH1, DHX58 and TRIM25 genes which possess properties on detecting viral dsRNA. On the other hand, the caIBDV arrested the host's apoptotic process by inducing the expression of apoptosis inhibitors including NFKBIA/Z, TNFAIP2/3 and ITA at the first 12 hours of infection. In conclusion, the differential expression landscape demonstrated with RNA-Seq provides a comprehensive picture on the molecular interactions between host cells and virus at the early stage of infection.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26053856 PMCID: PMC4460012 DOI: 10.1371/journal.pone.0111771
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Statistics on the RNA-Seq datasets.
| Mock-infected | caIBDV-infected | |||||
|---|---|---|---|---|---|---|
| hpi | Raw read | Trimmed read | Raw read | Trimmed read | ||
| 0 | R1 | 2,697,493 | 2,274,144 | R1 | 2,548,186 | 2,140,585 |
| R2 | 2,953,303 | 2,500,845 | R2 | 2,802,826 | 2,368,373 | |
| 6 | R1 | 2,643,354 | 2,250,936 | R1 | 2,524,045 | 2,166,168 |
| R2 | 2,861,666 | 2,445,301 | R2 | 2,730,637 | 2,351,470 | |
| 12 | R1 | 2,681,507 | 2,257,774 | R1 | 2,334,929 | 2,004,679 |
| R2 | 2,939,553 | 2,488,528 | R2 | 2,547,933 | 2,196,213 | |
Fig 1Number of unqiue matching reads and percentage of genome coverage to IBDV reference genome.
The demultiplexed, trimmed sequence reads were mapped to IBDV reference genome comprising two segments. No IBDV sequences were identified in the mock-infected group and at 0hpi of the caIBDV-infected group. The sequence reads mapped to segment A showed up at 6hpi, with 20.01% coverage of the segment. While at 12hpi, both segment A and B sequences were mapped covering 63.87% and 56.17% of the respective genome segments. Shaded: segment A; solid: segment B.
Number of genes and transcript isoforms mapped to reference genome Galgal4.73.
| Mock-infected | caIBDV-infected | |||||
|---|---|---|---|---|---|---|
| 0 hpi | 6 hpi | 12 hpi | 0 hpi | 6 hpi | 12 hpi | |
| Gene | 10,081 | 9,960 | 9,980 | 9,879 | 9,920 | 9,907 |
| Isoform | 10,350 | 10,228 | 10,245 | 10,147 | 10,194 | 10,181 |
Fig 2Pair-wise comparison of transcript expression in mock- and caIBDV-infected DF-1 cells at 0, 6 and 12 hours post-infection.
Comparison of expression data was performed by XY-scatterplot analysis of log base 2-transformed value of fragments per kilobase of transcript per million mapped fragments, FPKM. The solid line represents the predicted line of identity. The dashed line indicates the threshold of ≥ 2-fold or less than one-half of expression ratios. Data points shown in red represents significant differentially expressed transcripts, p < 0.05.
Fig 3Nine transcripts expressed in caIBDV-infected cells only at 12 hpi.
The expression level of these nine transcripts increased gradually from 0 to 12 hpi. ENSGALT00000006704: torsin family 1, member B-like mRNA; IYD: iodotyrosine deiodinase; RSAD2: radical SAM domain-containing 2, viperin; MXI1: MAX-interacting protein 1; ESR1: estrogen receptor 1; LYG2: lysozyme G-like 2; SAMD9L: sterile alpha motif domain containing 9-like uncharacterized protein; TNFAIP3: Tumor necrosis factor, alpha-induced protein 3; CCL19: Chemokine (C-C motif) ligand 19. White: mock-infected group; grey: caIBDV-infected group. x-axis: hours post-inoculation; y-axis: transcript level expressed as log2(fold change).
Fig 4Switching expressions of alternatively spliced froms of EFR3A gene.
(A) Structure and chromosomal location of the two transcripts of EFR3A gene; (B) Amino acid residue alignment of the N-terminal of the two transcripts; (C) Expression level (% of FPKM value) of the two transcripts in mock- and caIBDV-infected groups. White: EFR3A-201; grey: EFR3A-202.
Fig 5Heatmap indicating the pattern of 128 significant differentially expressed transcripts at 0, 6 and 12 hpi time points.
Expression fold change (log2 caIBDV/mock) are represented as indicated in the color scale. The transcripts were classified into 12 clusters according to their expression patterns.
Differentially expressed transcripts and the respective biological process upon caIBDV infection in DF-1 cells.
Transcripts with fold change at 12 hpi ≥ 4.00 are listed.
| Fold Change | ||||||
|---|---|---|---|---|---|---|
| Ensembl transcript ID | Symbol | Description | Biological function | 6hpi | 12hpi | Cluster |
| ENSGALT00000010311 | IFIT5 | Interferon-induced protein with tetratricopeptide repeats 5 | Anti-viral response | 4.05 | 9.75 | 3 |
| ENSGALT00000022096 | ISG12(2) | Putative ISG12-2 protein | Anti-viral response | 3.24 | 9.65 | 4 |
| ENSGALT00000025999 | MX | Interferon-induced GTP-binding protein Mx | Anti-viral response | 3.93 | 9.30 | 3 |
| ENSGALT00000015699 | ENSGALG00000009639 | Uncharacterized protein | Anti-viral response | - | 8.69 | 3 |
| ENSGALT00000009906 | HELZ2 | Helicase with zinc finger 2, transcriptional coactivator | Transcription regulation | 4.03 | 8.60 | 3 |
| ENSGALT00000018067 | IFIH1 | Interferon-induced helicase C domain-containing protein 1 | Anti-viral response | 3.01 | 8.27 | 4 |
| ENSGALT00000043751 | CMPK2 | Cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial | Anti-viral response | 3.34 | 8.26 | 3 |
| ENSGALT00000022305 | OAS*A | 59 kDa 2'-5'-oligoadenylate synthase-like protein | Anti-viral response | 3.49 | 8.20 | 3 |
| ENSGALT00000027416 | EPSTI1 | Epithelial stromal interaction 1 | Apoptosis | - | 7.76 | 6 |
| ENSGALT00000026025 | LY6E | Lymphocyte antigen 6E precursor | Transcription regulation | 4.50 | 7.40 | 2 |
| ENSGALT00000043789 | SLC46A2 | Solute carrier family 46, member 2 | Undescribed | - | 7.31 | 3 |
| ENSGALT00000019695 | TRANK1 | Tetratricopeptide repeat and ankyrin repeat containing 1 | Membrane protein/ receptor | 2.90 | 6.83 | 3 |
| ENSGALT00000019727 | DTX3L | Deltex 3-like protein | Transporter | 3.76 | 6.71 | 2 |
| ENSGALT00000002244 | IRF1 | Interferon regulatory factor 1 | Undescribed | 5.19 | 6.29 | 9 |
| ENSGALT00000010244 | K123 | K123 protein precursor | Respnose to DNA damage | 4.00 | 6.00 | 2 |
| ENSGALT00000024768 | ZPLD1 | Zona pellucida-like domain containing 1 | Anti-viral response | - | 5.91 | 5 |
| ENSGALT00000044367 | OLFML1 | Olfactomedin-like 1 | Undescribed | - | 5.88 | 7 |
| ENSGALT00000000519 | ITGB3 | Integrin beta-3 precursor | Undescribed | - | 5.62 | 7 |
| ENSGALT00000001439 | IGSF1 | Immunoglobulin superfamily member 1 | Undescribed | 4.36 | 5.60 | 9 |
| ENSGALT00000002240 | ENSGALG00000001478 | Uncharacterized protein | Membrane protein/ receptor | - | 5.48 | 4 |
| ENSGALT00000019721 | PARP14 | Poly (ADP-ribose) polymerase family, member 14 | Membrane protein/ receptor | 3.19 | 5.13 | 2 |
| ENSGALT00000000210 | DENND2D | DENN/MADD domain containing 2D | Undescribed | - | 5.04 | 1 |
| ENSGALT00000007763 | ZNFX1 | Zinc finger, NFX1-type containing 1 | Transcription regulation | 3.08 | 5.00 | 2 |
| ENSGALT00000021310 | USP18 | Ubiquitin carboxyl-terminal hydrolase 18 | GDP-GTP conversion | 2.57 | 4.96 | 3 |
| ENSGALT00000005325 | DHX58 | DEXH (Asp-Glu-X-His) box polypeptide 58 | Undescribed | - | 4.93 | 3 |
| ENSGALT00000006265 | SDC4 | Syndecan-4 precrusor | Interfereon Induced | - | 4.82 | 4 |
| ENSGALT00000018671 | LOC423478 | Exocyst complex component 3-like | Anti-viral response | 3.39 | 4.77 | 1 |
| ENSGALT00000002226 | STOML1 | Stomatin (EPB72)-like 1 | B-cell | - | 4.74 | 4 |
| ENSGALT00000044107 | BFIV21 | MHC BF2 class I precursor | Cellular balance | - | 4.69 | 6 |
| ENSGALT00000002368 | MOV10 | Putative helicase MOV-10 | Undescribed | 2.22 | 4.68 | 3 |
| ENSGALT00000042652 | KLF4 | Kruppel-like factor 4 | Peptide antigen binding | - | 4.62 | 10 |
| ENSGALT00000011423 | PXK | PX domain containing serine/threonine kinase | Antiviral response | - | 4.55 | 6 |
| ENSGALT00000039921 | HSPB1 | Heat shock protein 25 | RNA-mediated gene silencing | - | 4.55 | 7 |
| ENSGALT00000002125 | PML | Promyelocytic leukemia | Transcription regulation | - | 4.53 | 6 |
| ENSGALT00000039023 | IRF-3 | Interferon regulatory factor 3 | Apoptotic activity | 3.05 | 4.49 | 1 |
| ENSGALT00000024766 | NFKBIZ | NF-kappa-B inhibitor zeta | Inflammatory responses | - | 4.49 | 4 |
| ENSGALT00000004971 | TRIM25 | Tripartite motif containing 25 | Stress resistance | 3.32 | 4.49 | 2 |
| ENSGALT00000036426 | ITA | Inhibitor of apoptosis protein | Transcription regulation | - | 4.47 | 4 |
| ENSGALT00000020390 | NMI | N-myc (and STAT) interactor | Respnose to DNA damage | - | 4.35 | 4 |
| ENSGALT00000014519 | CASP7 | Caspase 7, apoptosis-related cysteine peptidase | - | 4.35 | 9 | |
| ENSGALT00000010406 | IRF10 | Interferon regulatory factor 10 | Interfereon-dependent immune responses | - | 4.32 | 4 |
| ENSGALT00000019729 | PARP9 | Poly (ADP-ribose) polymerase family, member 9 | NF-kappa-B cascade | - | 4.21 | 4 |
| ENSGALT00000040649 | CCL4 | Chemokine-like ligand 1 precursor | Apoptotic activity | - | 4.19 | 3 |
| ENSGALT00000010225 | PFKFB3 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 | Inflammatory responses | - | 4.13 | 5 |
| ENSGALT00000001016 | GBP7 | Guanylate binding protein 7 | Anti-viral response | - | 4.10 | 5 |
| ENSGALT00000022552 | ZC3HAV1 | Zinc finger CCCH-type antiviral protein 1 | Apoptotic activity | 2.51 | 4.04 | 1 |
Fig 6Gene pathways analysis.
The potential interaction among the significant differentially expressed isoforms (p < 0.05) were analysed with STRING tool v9.05. (A) 6 hpi; (B) 12 hpi. Expression fold change (log2 caIBDV/mock) are represented as indicated in the color scale. Red lines: potential protein interactions started at 6 hpi; green lines: potential protein interactions started at 12 hpi.